Repositioning Candidate Details
| Candidate ID: | R1071 |
| Source ID: | DB06652 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Vicriviroc |
| Synonyms: | Vicriviroc |
| Molecular Formula: | C28H38F3N5O2 |
| SMILES: | COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F |
| Structure: |
|
| DrugBank Description: | Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough. |
| CAS Number: | 306296-47-9 |
| Molecular Weight: | 533.6288 |
| DrugBank Indication: | Investigated for use/treatment in HIV infection and viral infection. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Vicriviroc is a once daily oral inhibitor of CCR5. It noncompetitively binds to a hydrophobic pocket between transmembrance helices by the extracellular side of CCR5. This allosteric antagonism causes a conformational change in the protein preventing binding of gp120 to CCR5. This prevents the entry of HIV into the cell. |
| Targets: | C-C chemokine receptor type 5 |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|